Maxygen news from FierceBiotech
NewsMaxygen inks $180M deal with Astellas
Maxygen is pocketing a $10 million upfront fee from Japan's Astellas for marketing rights to its Maxy-4 therapies--a preclinical program focused on developing a next-generation CTLA4-Ig protein for... Read more...
Maxygen inks $120M deal for hemophilia program
Maxygen has inked a deal to sell its hemophilia drug development program to Bayer for $90 million upfront and up to $30 million in milestone payments. The program is still in the preclinical stage,... Read more...
Mpex in pact with GSK; Biogen favored in Icahn spat; Maxygen shares slide on threatened patent dispute;
> Mpex has inked a collaboration deal with GlaxoSmithKline. The collaboration provides GlaxoSmithKline access to Mpex's novel efflux pump inhibitors and related technology for use in combination... Read more...
C&L: Lundbeck CEO resigns early
Denmark's H Lundbeck announced that its president and chief executive Claus Braestrup has resigned earlier than expected. Critical Therapeutics announced that Frank Thomas will resign as president... Read more...
Maxygen, Sanofi Pasteur ink $24.5M vaccine deal
Maxygen has agreed to transfer a portfolio of preclinical dengue antigens to Sanofi Pasteur for use developing a second generation vaccine. Maxygen stands to gain up to $24.5 million in the deal. The... Read more...
SPOTLIGHT: Maxygen closes Denmark facility
Maxygen is shutting down its Denmark facility--which has largely focused on preclinical activities--and is adding 25 staffers to its Redwood City headquarters as it restructures.
Roche halts Phase I trial
Roche has halted a trial of MAXY-alpha, also known as R7025, due to an unanticipated reduction of the pharmacodynamic and pharmacokinetic effects in patients who received the drug. Roche and... Read more...
| Press ReleasesMaxygen Receives $3.4 Million Government Grant to Develop Vaccine Discovery TechnologyMaxygen Receives $3.4 Million Government Grant to Develop Vaccine Discovery Technology REDWOOD CITY, Calif., Aug 27, 2008 (BUSINESS WIRE) -- Maxygen a biotechnology company focused on the development Read more >> PRESS RELEASE: Maxygen Licenses Dengue Vaccine Technology to Sanofi Pasteur for up to $24.5 M Maxygen Licenses Dengue Vaccine Technology to Sanofi Pasteur for up to $24.5 M REDWOOD CITY, Calif., Dec. 4 -- Maxygen, a biotechnology company focused on the development of improved protein drugs, Read more >> PRESS RELEASE: Maxygen and Roche Terminate Development of Hepatitis Drug Maxygen and Roche Terminate Development of Hepatitis Drug REDWOOD CITY, Calif., Nov. 26 -- Maxygen, Inc. announced today that Roche and Maxygen have agreed to terminate development of MAXY-alpha, Read more >> PRESS RELEASE: Maxygen Says Partner Roche Puts Hold Hepatitis Drug Trial Maxygen Says Partner Roche Puts Hold Hepatitis Drug Trial REDWOOD CITY, Calif., Sept. 21 -- Roche has advised Maxygen, Inc. that it has voluntarily placed a hold on further clinical development of Read more >> |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
